In another 12-week study on hormone therapy with either Rx or tibolone in postmenopausal women, the group with a history of venous thrombosis showed an increase in sex hormone binding globulin (SHBG), which in turn was associated with a change in APC resistance, proposing that SHBG can be used as a biomarker to identify an increased risk in venous thrombosis in hormone therapy [29]. The gene discussed is SHBG; the disease is Venous thrombosis.